AffaMed Therapeutics announced that the first patient has been treated in the Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA in subjects following ophthalmic surgery. In October 2020, AffaMed Therapeutics entered into an exclusive license agreement with Ocular Therapeutix (OCUL) for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets. DEXTENZA is approved in the U.S. and Macau for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCUL:
- Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
- Ocular Therapeutix reports Q2 EPS (26c), consensus (30c)
- Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
- OCUL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cantor biotech/biopharma analysts to hold analyst/industry conference call